Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pregnancy Labeling Gets A New Look

Executive Summary

FDA’s final rule includes narrative summaries of risk information about use during pregnancy and lactation, and it creates a new section relevant to drug effects on reproductive potential.

You may also be interested in...



Pregnancy Labeling: US FDA Ponders Whether Changes Needed To Overcome Risk Misperceptions

Risk Communication Advisory Committee will opine on impact that Pregnancy and Lactation Labeling Rule has had in conveying safety evidence useful to making prescribing decisions for pregnant patients and whether current labeling language can be improved upon.

Pregnancy Labeling Changes May Spur Research, FDA Says

Final regulation eliminates use of letter-based categories to designate level of risk during pregnancy and lactation; in a change from the 2008 proposed rule, information relevant to drug effects on reproductive potential will now be housed in dedicated section.

US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’

Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS056525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel